Addresses a large AMD patient population with limited current treatment options. Current Wet AMD treatments are effective only on patients who are newly-diagnosed with Wet AMD, of which there are approximately 200,000 in the United States each year. RHEO Therapy, however, is a treatment for most patients in the Category 3 and Category 4 Dry AMD population, which, according to the AREDS Report, represents approximately 54% of the total U.S. Dry AMD patients, or currently approximately 8 million people. RHEO Therapy is not appropriate for everyone in the Category 3 and Category 4 Dry AMD population. For example, RHEO Therapy would not be appropriate for potential patients who may have existing ailments that would make it unsafe for them to receive any blood transfusion type procedure

EX-2.1 3 t14639exv2w1.txt EX-2.1 EXHIBIT 2.1 PLAN OF REORGANIZATION This PLAN OF REORGANIZATION (this "Agreement"), dated effective as of [__], 2004, by and among TLC VISION CORPORATION, a corporation formed under the laws of the Province of New Brunswick, OCCULOGIX, INC., a corporation existing under the laws of Delaware, and OCCULOGIX, L.P., a Delaware limited partnership. RECITALS: WHEREAS, the parties hereto intend for TLC Vision Corporation to effect the sale of and Occulogix, Inc. to acquire TLC Vision Corporation's 50 percent indirect interest in Occulogix, L.P.(the "Acquisition"); WHEREAS, the parties desire to enter into this Agreement with respect to the transactions contemplated by the Acquisition as set forth below; NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereto agree that the final transaction steps are as follows: Section 1. Steps of Reorganization. a. Occulogix L.P. ("OLP") will contribute all its assets (including its intellectual property), other than the assets representing the Canadian branch, to Occulogix U.S. LLC, a newly formed Delaware limited liability company ("US LLC"), and US LLC will assume all liabilities other than liabilities relating to the Canadian branch, in exchange for 100 membership units. OLP and US LLC will enter into a license for the use by OLP of the intellectual property in Canada. The license will be a royalty free license (presumably short-term). b. OLP will distribute 50 membership units of US LLC to each of TLC Apheresis, L.P. ("TLC LP") and Occulogix Holdings, Inc. ("Holdings"). c. TLC LP will distribute 50 membership units of US LLC to TLC Apheresis (USA) Inc. ("TLC USA Inc.") in exchange for the TLC LP limited partnership interest owned by TLC USA Inc., and TLC USA Inc. will withdraw as a limited partner in TLC LP. As a result, TLC USA Inc. and Holdings will be equal members in US LLC, and TLC Vision Corporation ("TLC Canada") will own the entire limited partner interest in TLC LP with TLC Apheresis Inc. as the general partner. d. TLC USA Inc. will merge with and into Holdings, and TLC Vision will receive Occulogix, Inc. ("OI") common shares in exchange for its TLC USA Inc. shares. As a result of the merger, Holdings will own all the units of US LLC, and US LLC will be disregarded for U.S. federal income tax purpose. e. OI will organize a newly formed Nova Scotia unlimited liability company, OccuLogix Exchangeco ULC ("OI NSULC"), which for U.S. federal income tax purposes will be a pass-through entity and will allocate all its income and loss to OI. f. OI NSULC will be appointed general partner of TLC LP. As a result, TLC LP's general partner will be OI NSULC and limited partner will be TLC Canada. g. TLC LP will liquidate and distribute the OLP limited partnership interest and Occulogix Management Inc. ("OGP") shares to TLC Canada. h. TLC Canada will transfer its OLP limited partnership interest and OGP shares to OI NSULC in exchange for OI NSULC units that are exchangeable into OI shares. In conjunction with the issuance of the exchangeable units, OI will be provided an overriding contractual right to purchase the OI NSULC exchangeable units from TLC Canada in exchange for OI stock where TLC Canada first exercises its exchange right under the terms of the exchangeable units against OI NSULC. Section 2. Conditions of Closing. The parties agree that the completion of the Acquisition is conditional upon delivery of appropriate tax and corporate opinions being delivered by Torys LLP and acceptable to all parties. Section 3. Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the parties named herein and their respective successors and permitted assigns. Neither Party may assign this Agreement or any of its rights, interests or obligations hereunder without the prior written approval of the other party. Section 4. Headings. The section headings in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. Section 5. Entire Agreement. This Agreement constitutes the entire agreement among the parties with respect to the subject matters hereof, and supersedes any prior understandings, term sheets, agreements or representations by and between the parties, written or oral, to the extent they related in any way to the subject matter hereof. Section 6. Waiver, Amendment. Except as expressly provided in this Agreement, no amendment or waiver of this Agreement shall be binding unless executed in writing by the party to be bound thereby. No waiver of any provision of this Agreement shall constitute a waiver of any other provision nor shall any waiver of any provision of this Agreement constitute a continuing waiver unless otherwise expressly provided. Section 7. Severability. If any provisions of this Agreement for any reason is held illegal or unenforceable, such provision shall be deemed separable from the remaining provisions of this Agreement and shall in no way affect or impair the validity or the enforceability of the remaining provisions of this Agreement. Section 8. Construction. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if jointly drafted by the parties and no presumption or burden of proof shall arise favoring or disfavoring either party by virtue of the authorship of any provision of this Agreement. Any reference to any federal, state, local or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Section 9. Governing Law. This Agreement shall be governed by and construed in accordance with the domestic laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York. Section 10. Counterparts. This Agreement may be executed, including by facsimile signature, in one or more counterparts, each of which shall be deemed an original but all of which together, shall constitute one and the same instrument. Section 11. Further Assurances. Each of the parties hereto shall promptly do, make, execute or deliver, or cause to be done, made, executed or delivered, all such further acts, documents and things as the other party hereto may reasonably require from time to time for the purpose of giving effect to this Agreement and shall use reasonable efforts and take all such steps as may be reasonably within its power to implement to their full extent the provisions of this Agreement. [SIGNATURE PAGE FOLLOWS] The undersigned parties have executed this Plan of Reorganization as of the date first set forth above. OCCULOGIX, INC. TLC VISION CORPORATION By: _______________________________ By: _________________________________ Name: Name: Title: Title: OCCULOGIX, L.P. By: _________________________________ Name: Title: